Clinical Trial Update: Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2) [Phase 3]

View source ↗

Summary

Phase 3 trial POLO-AML-2 evaluated volasertib plus low-dose cytarabine in patients 65+ with untreated acute myeloid leukemia ineligible for intensive therapy; s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Low-dose cytarabine (Cytarabine (low-dose))
• Volasertib (Volasertib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Leukemia, Myeloid, Acute | Phase 3 | Status: COMPLETED | Results posted: 2021-11-19